

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
STAPPER et al.

Examiner: UNASSIGNED

Art Unit: UNASSIGNED

Application No.: NOT YET ASSIGNED

Filed: **FEBRUARY 27, 2004**

Title: **ARYLCYCLOALKYL-SUBSTITUTED
ALKANOIC ACID DERIVATIVES,
PROCESSES FOR THEIR PREPARATION
AND THEIR USE AS
PHARMACEUTICALS**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on

2/27/04
Date of Deposit

Manuel Mendez
Signature

EL 964822471 US
Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

Barbara E. Kurys

Barbara E. Kurys, Reg. No. 34,650
Attorney For Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0019USNP